Document is current
Any future updates will be listed below
-
Authors
Plage, Henning
Furlano, Kira
Hofbauer, Sebastian
Weinberger, Sarah
Ralla, Bernhard
Franz, Antonia
Fendler, Annika
de Martino, Michela
Roßner, Florian
Elezkurtaj, Sefer
Kluth, Martina
Lennartz, Maximilian
Blessin, Niclas C.
Marx, Andreas H.
Samtleben, Henrik
Fisch, Margit
Rink, Michael
Slojewski, Marcin
Kaczmarek, Krystian
Ecke, Thorsten
Hallmann, Steffen
Koch, Stefan
Adamini, Nico
Zecha, Henrik
Minner, Sarah
Simon, Ronald
Sauter, Guido
Weischenfeldt, Joachim
Klatte, Tobias
Schlomm, Thorsten
Horst, David
Schallenberg, Simon
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 4 May 2023
Accepted: 11 April 2024
First Online: 24 April 2024
Declarations
:
: Patient’s consent to participate was not required according to local laws (HmbKHG, §12, article 1), because patient samples were anonymized for the study. The use of archived remnants of diagnostic tissues for manufacturing of TMAs and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, §12, article 1) and by the local ethics committee (Ethics commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.
: Not applicable.
: The recombinant rabbit monoclonal PD-L1 antibody, MSVA-711R was from MS Validated Antibodies GmbH, Hamburg, Germany (owned by a family member of GS). All other authors have no conflict of interest.
